MIT Successfully Completes Rigorous Performance Tests

SAN CLEMENTE, CA--(Marketwire - December 17, 2007) - Micro Imaging Technology, Inc. (OTCBB: MMTC) announces the successful completion of rigorous microorganism identification accuracy testing. The Company tested three MIT Rapid Microbial ID Systems for identification accuracy on a total of eight different species' strains of E.coli, Staphylococcus aureus and Salmonella. The MIT 1000 System produces results in less than ten minutes after completion of the culturing process without using chemicals, reagents or DNA processing.

The objectives of the test were twofold. The first objective was to determine the System's ability to accurately identify specific bacterial species strains that were programmed into the System's database. The second objective was to determine the System's robustness to accurately identify the correct species when presented with a strain of that species not programmed into the System's database. The organisms were chosen based on customer interest and frequency of reported contamination cases found in food processing, food products, hospitals, and other public environments.

Of the 151 tests performed, 40% were tested with the actual species strain. The remaining tests provided accuracy performance of specific species strains not in the System's database. The results showed that the three systems achieved 100% identification accuracy for all species when the specific strain was programmed into the Product's database and 91% accuracy for all testing conducted.

MIT's CTO Dr. David Haavig stated, "The perfect results achieved for those species strains within our database met our expectations and we are pleased to see the robust performance of the MIT 1000 System when presented with a species strain not contained in the database. This will enable our customers to confidently use our System with a wide variety of organisms and obtain consistent and reliable identification results. This performance also suggests that minor adjustments to our algorithms may improve the performance to obtain near 100% accuracy for all strains of a species."

About Micro Imaging Technology

The Company has developed and patented a technology for rapid microbe detection and identification. This System measures scattered light intensity as individual microbes pass through a laser beam. The intensity pattern of the scattered light is a direct consequence of the size, shape and external and internal optical characteristics of the microbe. The MIT System is non-biological and does not rely on biological agents, conventional chemical processing, fluorescent tags, gas chromatography or DNA analysis.

MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, Shigella and other pathogenic bacteria. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The Test Report, in the Company's opinion, demonstrated the accuracy, speed and efficiency of the MIT System over conventional processes and is available from the Company. The MIT 1000 System was recently featured in a Rapid Microbiology international newsletter and can be viewed at http://www.rapidmicrobiology.com/news/1231h0.php?s=MIT.

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

Contact Information: CONTACT: Michael Brennan Chairman Email: Telephone: (805) 557-0614